Hutchin Hill Capital’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q3
Sell
-30,000
Closed -$2.17M 715
2017
Q2
$2.17M Buy
30,000
+2,400
+9% +$161K 0.07% 290
2017
Q1
$1.8M Buy
+27,600
New +$1.74M 0.05% 354
2015
Q3
Sell
-225,000
Closed -$15.1M 575
2015
Q2
$15.1M Buy
+225,000
New +$14.7M 0.39% 69
2015
Q1
Sell
-801,000
Closed -$52.4M 643
2014
Q4
$52.4M Buy
801,000
+456,000
+132% +$28.7M 1.87% 5
2014
Q3
$19.9M Sell
345,000
-455,000
-57% -$25.3M 0.75% 41
2014
Q2
$45.2M Buy
800,000
+320,000
+67% +$16.8M 2.06% 6
2014
Q1
$24.7M Buy
+480,000
New +$24.3M 1.28% 21

Other funds holding ABBV

Hutchin Hill Capital's ABBV Position: Q3 2017 in Review

Hutchin Hill Capital sold out of AbbVie (ABBV) in Q3 2017, closing a stake of 30,000 shares — an estimated $2.17M sold.

Hutchin Hill Capital first reported a position in ABBV in Q1 2014 and held it in 7 quarters. The position peaked at $52.4M in Q4 2014. 1,798 funds tracked by Wall St. Rank hold ABBV as of Q3 2017.

  • Hutchin Hill Capital reported no remaining AbbVie position as of Q3 2017 after selling out during the quarter.
  • Hutchin Hill Capital sold 30,000 AbbVie shares in Q3 2017, an estimated $2.17M.
  • Hutchin Hill Capital first reported a position in AbbVie in Q1 2014 and held it in 7 quarters.
  • Hutchin Hill Capital's AbbVie position peaked at $52.4M in Q4 2014.
  • 1,798 funds tracked by Wall St. Rank held AbbVie as of Q3 2017.

Based on Hutchin Hill Capital's 13F filing for Q3 2017, filed 14 Nov 2017.